Nevro (NVRO) Revenue & Revenue Breakdown
Nevro Revenue Highlights
Latest Revenue (Y)
$425.17M
Latest Revenue (Q)
$104.16M
Main Segment (Y)
Painful Diabetic Neuropathy
Main Geography (Y)
UNITED STATES
Nevro Revenue by Period
Nevro Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $425.17M | 4.63% |
| 2022-12-31 | $406.37M | 5.03% |
| 2021-12-31 | $386.90M | 6.87% |
| 2020-12-31 | $362.05M | -7.23% |
| 2019-12-31 | $390.25M | 0.77% |
| 2018-12-31 | $387.29M | 18.56% |
| 2017-12-31 | $326.67M | 42.96% |
| 2016-12-31 | $228.50M | 228.28% |
| 2015-12-31 | $69.61M | 113.69% |
| 2014-12-31 | $32.57M | 38.61% |
| 2013-12-31 | $23.50M | 29.48% |
| 2012-12-31 | $18.15M | - |
Nevro generated $425.17M in revenue during NA 2023, up 4.63% compared to the previous quarter, and up 109.78% compared to the same period a year ago.
Nevro Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $104.16M | 2.22% |
| 2024-03-31 | $101.90M | -12.29% |
| 2023-12-31 | $116.18M | 11.86% |
| 2023-09-30 | $103.86M | -4.55% |
| 2023-06-30 | $108.81M | 12.96% |
| 2023-03-31 | $96.33M | -15.39% |
| 2022-12-31 | $113.84M | 13.32% |
| 2022-09-30 | $100.47M | -3.60% |
| 2022-06-30 | $104.21M | 18.64% |
| 2022-03-31 | $87.84M | -14.52% |
| 2021-12-31 | $102.76M | 10.25% |
| 2021-09-30 | $93.20M | -8.92% |
| 2021-06-30 | $102.33M | 15.48% |
| 2021-03-31 | $88.61M | -19.25% |
| 2020-12-31 | $109.73M | 1.17% |
| 2020-09-30 | $108.46M | 92.34% |
| 2020-06-30 | $56.39M | -35.53% |
| 2020-03-31 | $87.47M | -23.53% |
| 2019-12-31 | $114.37M | 14.19% |
| 2019-09-30 | $100.16M | 7.04% |
| 2019-06-30 | $93.57M | 13.91% |
| 2019-03-31 | $82.15M | -23.90% |
| 2018-12-31 | $107.94M | 12.88% |
| 2018-09-30 | $95.63M | -0.47% |
| 2018-06-30 | $96.08M | 9.64% |
| 2018-03-31 | $87.64M | -10.54% |
| 2017-12-31 | $97.96M | 19.10% |
| 2017-09-30 | $82.26M | 5.43% |
| 2017-06-30 | $78.02M | 13.99% |
| 2017-03-31 | $68.44M | -2.97% |
| 2016-12-31 | $70.53M | 15.77% |
| 2016-09-30 | $60.92M | 9.97% |
| 2016-06-30 | $55.40M | 33.01% |
| 2016-03-31 | $41.65M | 25.74% |
| 2015-12-31 | $33.12M | 115.06% |
| 2015-09-30 | $15.40M | 34.89% |
| 2015-06-30 | $11.42M | 18.17% |
| 2015-03-31 | $9.66M | -0.55% |
| 2014-12-31 | $9.71M | 12.08% |
| 2014-09-30 | $8.67M | 15.17% |
| 2014-06-30 | $7.53M | 12.94% |
| 2014-03-31 | $6.66M | 7.55% |
| 2013-12-31 | $6.20M | -0.03% |
| 2013-09-30 | $6.20M | - |
Nevro generated $104.16M in revenue during Q2 2024, up 2.22% compared to the previous quarter, and up 108.13% compared to the same period a year ago.
Nevro Revenue Breakdown
Nevro Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Painful Diabetic Neuropathy | $77.90M | $48.00M | $5.70M |
Nevro's latest annual revenue breakdown by segment (product or service), as of Dec 23: Painful Diabetic Neuropathy (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|
| Painful Diabetic Neuropathy | $22.50M | $20.80M | $19.00M | $15.60M | $17.60M | $13.40M | $11.00M | $6.00M | $1.70M |
Nevro's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Painful Diabetic Neuropathy (100.00%).
Nevro Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $58.62M | $58.20M | - | - | - |
| UNITED STATES | $366.56M | $348.17M | $326.22M | $311.87M | $326.01M |
| Non Us | - | - | $60.69M | $50.17M | $64.24M |
Nevro's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (86.21%), and Non-US (13.79%).
Quarterly Revenue by Country
| Country | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $83.90M | $87.04M | $101.52M | $89.76M | $92.96M | $82.32M | $99.77M | $86.13M | $89.05M | $73.21M | $91.62M | $79.62M | $79.91M | $70.62M |
| Non-US | $13.01M | $14.86M | $14.66M | $14.10M | $15.85M | $14.01M | $14.07M | $14.34M | $15.16M | - | - | - | - | - |
| Non Us | - | - | - | - | - | - | - | - | - | $14.63M | $16.32M | $16.01M | $16.17M | $17.01M |
Nevro's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (86.57%), and Non-US (13.43%).
Nevro Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ITGR | Integer | $1.60B | $746.27M |
| CNMD | CONMED | $1.24B | $316.70M |
| LIVN | LivaNova | $1.15B | $318.11M |
| NVRO | Nevro | $425.17M | $104.16M |
| GKOS | Glaukos | $314.71M | $96.67M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SRDX | Surmodics | $126.08M | $30.34M |
| RXST | RxSight | $89.08M | $45.41M |
| SGHT | Sight Sciences | $81.06M | $20.16M |
| LUNG | Pulmonx | $68.67M | $20.39M |
| IRMD | IRadimed | $65.56M | $18.33M |
| NPCE | NeuroPace | $65.42M | $21.06M |
| CVRX | CVRx | $39.30M | $13.37M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |